Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
暂无分享,去创建一个
R. Eliakim | U. Kopylov | S. Ben-Horin | R. Loebstein | Y. Chowers | I. Levy | M. Yavzori | B. Ungar | Y. Yavne | O. Picard | E. Fudim
[1] G. D'Haens,et al. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment. , 2015, Journal of Crohn's & colitis.
[2] J. Barkin,et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[3] K. Van Steen,et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.
[4] R. Gearry,et al. Disease Activity Assessment in IBD: Clinical Indices and Biomarkers Fail to Predict Endoscopic Remission , 2015, Inflammatory bowel diseases.
[5] R. Eliakim,et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[6] P. Rutgeerts,et al. Factors associated with short- and long-term outcomes of therapy for Crohn's disease. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[7] G. Greenberg,et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease , 2014, Gut.
[8] G. D'Haens,et al. A Systematic Review of Measurement of Endoscopic Disease Activity and Mucosal Healing in Crohn's Disease: Recommendations for Clinical Trial Design , 2014, Inflammatory bowel diseases.
[9] U. Kopylov,et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease , 2014, Alimentary pharmacology & therapeutics.
[10] G. D'Haens,et al. A Systematic Review of the Measurement of Endoscopic Healing in Ulcerative Colitis Clinical Trials: Recommendations and Implications for Future Research , 2014, Inflammatory bowel diseases.
[11] S. Brand,et al. Rate and Predictors of Mucosal Healing in Patients with Inflammatory Bowel Disease Treated with Anti-TNF-Alpha Antibodies , 2014, PloS one.
[12] P. Rutgeerts,et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial , 2014, Gut.
[13] L. Peyrin-Biroulet,et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[14] U. Kopylov,et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab , 2013, Gut.
[15] W. Sandborn,et al. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[16] R. Eliakim,et al. Clinical utility of antihuman lambda chain‐based enzyme‐linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti‐infliximab antibodies , 2012, Inflammatory bowel diseases.
[17] A. Griffiths,et al. Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. , 2012, Journal of Crohn's & colitis.
[18] M. Färkkilä,et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease , 2012, Scandinavian journal of gastroenterology.
[19] G. Van Assche,et al. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease , 2012, Inflammatory bowel diseases.
[20] P. Rutgeerts,et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. , 2011, Gastroenterology.
[21] U. Kopylov,et al. The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful , 2010, Gut.
[22] Stefan Schreiber,et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[23] P. Rutgeerts,et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.
[24] P. Rutgeerts,et al. Mucosal healing predicts long‐term outcome of maintenance therapy with infliximab in Crohn's disease , 2009, Inflammatory bowel diseases.
[25] K. Van Steen,et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.
[26] P. Rutgeerts,et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.
[27] M. Silverberg,et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[28] Paul Rutgeerts,et al. Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.
[29] M. Schwartz,et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis , 2005, Gut.
[30] R. F. Harvey,et al. A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.